Caris Life Sciences and the Beat Childhood Cancer Research Consortium at Penn State University join forces to enhance outcomes for pediatric patients
Wednesday, March 06, 2024
Caris Life Sciences®, a leader in AI TechBio and precision medicine, has announced a collaboration with the Beat Childhood Cancer Research Consortium, based at Penn State College of Medicine. This partnership aims to advance precision oncology and biomarker-driven research to improve outcomes for children with cancer.
As part of this collaboration, Caris will work as the molecular analysis partner for Beat Childhood Cancer Research Consortium studies. Through Caris' comprehensive genomic, transcriptomic, and proteomic profiling capabilities, the research consortium can enhance therapeutic options and identify potentially beneficial clinical trial opportunities for pediatric cancer patients.
Milan Radovich, PhD, SVP and Chief Scientific Officer at Caris Life Sciences, expressed enthusiasm about partnering with the Beat Childhood Cancer Research Consortium to tailor treatment plans using the latest targeted agents and therapeutics.
Giselle Saulnier Sholler, MD, MSc, Chair of the Beat Childhood Cancer Research Consortium, highlighted the significance of sequencing tumors and molecular tumor board review in improving patient care. The collaboration aims to deepen the understanding of pediatric cancer and advance precision medicine initiatives.
Dr. Yatin M. Vyas, Vice President of Penn State Health Children's, emphasized the importance of precision medicine in pediatric cancer research, aligning with the consortium's goal of eliminating cancers in children.
George W. Sledge, Jr., MD, EVP and Chief Medical Officer of Caris, underscored the alignment between Caris' mission and the vision of the Beat Childhood Cancer Research Consortium in improving cancer outcomes through genomic research.
The Beat Childhood Cancer Research Consortium, known for its successful management of multi-site clinical trials, has opened several trials for pediatric cancer patients, including those utilizing molecular-guided therapy for relapsed cancer.
Caris' extensive dataset, generated from the sequencing of numerous cancer patients over the past decade, contributes to advancing understanding of cancer's molecular composition and enables more tailored and effective treatments.
Source: prnewswire.com
